
|Videos|January 3, 2017
A Study Investigating Pembrolizumab in Combination With Eribulin in TNBC
Author(s)Sara Tolaney, MD, MPH
Sara Tolaney, MD, MPH, associate clinical research director of Breast Oncology at the Dana-Farber Cancer Institute in Boston, discusses a clinical trial investigating pembrolizumab in combination with eribulin in triple-negative breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
5







































